Keryx Biopharmaceuticals (KERX) to resume trading at 7:30AM
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) to resume trading at 7:30AM ET following positive Phase 3 data. The long-term Phase 3 study of Zerenex met primary and secondary endpoints.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
- FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease
- 18 people were killed in Iran - Trump
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
